Trevi Therapeutics surges on earnings beat, FDA Phase 3 alignment
Biotech company ends 2025 with $188M cash runway as chronic cough treatment advances to pivotal trials
Trevi Therapeutics shares advanced in Tuesday trading after the clinical-stage biopharmaceutical company reported quarterly results that exceeded analyst expectations and revealed significant regulatory progress for its lead drug candidate.
The New Haven-based company reported a fourth-quarter loss of 6 cents per share, narrower than the 10-cent loss analysts had anticipated, representing a 40.8% beat on EPS estimates. The company's net loss narrowed to $8.3 million from $11.4 million in the same period a year earlier, reflecting disciplined expense management as it advances its clinical programs.
Perhaps more significantly for long-term investors, Trevi ended 2025 with $188.3 million in cash and marketable securities, providing a financial runway that extends into 2028. This cash position should comfortably fund two pivotal Phase 3 clinical trials for Haduvio (oral nalbuphine ER) in treating idiopathic pulmonary fibrosis (IPF)-related chronic cough, with the first trial expected to commence in the second quarter of 2026.
The financial report comes on the heels of a critical regulatory milestone. Following an End-of-Phase 2 meeting with the U.S. Food and Drug Administration, Trevi achieved alignment on its Phase 3 development program for Haduvio in IPF-related chronic cough. The agreement covers the design of two parallel pivotal trials, with the second study targeted for initiation in the second half of 2026. The company also gained FDA agreement on remaining Phase 1 studies required to support a New Drug Application submission.
"We enter 2026 with a strong balance sheet and clear regulatory path forward," said Jennifer Good, Trevi's president and chief executive officer. "The FDA's alignment on our Phase 3 program de-risks our development timeline and positions us to potentially address a significant unmet medical need for IPF patients suffering from chronic cough."
The competitive landscape for chronic cough treatments has shifted dramatically in recent months. Merck's gefapixant, while approved in Japan and Europe for refractory chronic cough, failed to demonstrate efficacy in IPF patients and subsequently withdrew its U.S. new drug application. This development has narrowed the field and potentially enhanced Trevi's first-mover advantage in the IPF-specific indication.
Trevi's Haduvio has demonstrated "meaningful clinical benefit" in reducing chronic cough frequency in clinical trials, particularly among IPF patients. The oral extended-release formulation of nalbuphine represents a different mechanism of action from P2X3 receptor antagonists, the class that includes competitors such as GSK's camlipixant and Shionogi's S-600918.
The market opportunity for chronic cough treatments is substantial. The chronic refractory cough market is projected to reach $14.9 billion by 2035, driven by increasing research and development activities and the limited treatment options currently available. IPF affects approximately 100,000 Americans, and chronic cough is one of the most debilitating symptoms of the progressive lung disease.
Analysts remain broadly optimistic about Trevi's prospects. The stock currently carries an average price target of $21.55, representing roughly 92% upside from current levels, with all 11 covering analysts rating the shares a buy, according to MarketBeat data. The company's institutional ownership stands at 104%, indicating strong demand from large investors.
Trevi's full-year 2025 results showed a net loss of $47.91 million, or 47 cents per share, with total operating expenses of $51.5 million. The company has guided for earnings per share to decline slightly in the coming year, ranging from a loss of 49 cents to 51 cents per share, as it invests in the Phase 3 trials.
Looking ahead, investors will be watching for the initiation of the first Phase 3 trial in Q2 2026 and updates on patient enrollment timelines. The parallel trial design could potentially accelerate the development timeline compared to sequential approaches, though it also requires greater upfront investment. With nearly three years of cash runway and a clear regulatory path, Trevi appears positioned to execute on its clinical development program without immediate need for additional capital.
The company's stock has traded within a 52-week range of $4.85 to $14.39, and Tuesday's advance brings its market capitalization to approximately $1.4 billion.